PRTA PROTHENA CORP PUBLIC LTD CO
Pharmaceutical Preparations · Nasdaq · SEC CIK 1559053 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY347.4%
TTM net income YoY91.5%
TTM EPS YoY91.3%
Revenue 3-yr CAGR-27.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-64.6%
Net margin-45.4%
FCF margin—
EBITDA margin-63.1%
Returns
ROE-8.5%
ROA-7.5%
ROIC (approx.)—
Asset turnover0.17x
Leverage & solvency
Liabilities / assets5.2%
Debt / equity0.00x
Current ratio23.95x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.31x
Accruals ratio2.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $9.68M | $135.16M |
| R&D expense | $134.85M | $222.52M |
| SG&A expense | $59.39M | $67.20M |
| Operating income | -$214.64M | -$154.56M |
| Pretax income | -$200.83M | -$128.93M |
| Income tax | $43.26M | -$6.62M |
| Net income | -$244.09M | -$122.31M |
| EBITDA | -$213.75M | -$153.67M |
| EPS (basic) | -4.53 | -2.27 |
| EPS (diluted) | -4.53 | -2.27 |
| Weighted avg. shares (diluted) | 53.83M | 53.77M |
| Banking | ||
| Net interest income | $14.14M | $25.82M |
| Balance sheet | ||
| Cash & equivalents | $307.53M | $472.25M |
| Receivables | — | $0 |
| Current assets | $315.19M | $485.41M |
| PP&E, net | $2.14M | $3.08M |
| Total assets | $326.80M | $547.11M |
| Current liabilities | $40.84M | $48.50M |
| Total liabilities | $46.33M | $60.18M |
| Shareholders' equity | $280.47M | $486.93M |
| Shares outstanding | 53.83M | 53.83M |
| Cash flow statement | ||
| Operating cash flow | -$163.58M | -$150.05M |
| Investing cash flow | -$138,000 | -$298,000 |
| Financing cash flow | -$139,000 | $1.55M |
| Depreciation & amortization | $895,000 | $893,000 |
| Stock-based compensation | $37.64M | $45.96M |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.